Fox Run Management L.L.C. Acquires New Stake in Pfizer, Inc. (PFE)

Fox Run Management L.L.C. acquired a new position in Pfizer, Inc. (NYSE:PFE) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 15,900 shares of the biopharmaceutical company’s stock, valued at approximately $534,000.

Other hedge funds also recently bought and sold shares of the company. Asset Planning Services Ltd. increased its position in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 137 shares during the last quarter. Orrstown Financial Services Inc. boosted its stake in Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 612 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC purchased a new stake in Pfizer in the first quarter worth approximately $121,000. Cable Hill Partners LLC boosted its stake in Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 265 shares in the last quarter. Finally, Patten Group Inc. boosted its stake in Pfizer by 5.1% in the first quarter. Patten Group Inc. now owns 5,181 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 252 shares in the last quarter. Institutional investors own 69.00% of the company’s stock.

Several analysts have issued reports on the company. Jefferies Group LLC set a $35.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. Sanford C. Bernstein set a $39.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Tuesday. Berenberg Bank set a $39.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, August 1st. Morgan Stanley reaffirmed a “neutral” rating and issued a $35.00 target price (down previously from $38.00) on shares of Pfizer in a research note on Monday, June 12th. Finally, Vetr lowered Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price for the company. in a research note on Wednesday, September 13th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $37.83.

In other news, CEO Ian C. Read sold 96,950 shares of the company’s stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $34.00, for a total value of $3,296,300.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Ian C. Read sold 197,168 shares of the company’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $34.00, for a total value of $6,703,712.00. Following the completion of the sale, the chief executive officer now owns 580,318 shares in the company, valued at approximately $19,730,812. The disclosure for this sale can be found here. Insiders sold 464,521 shares of company stock worth $15,813,961 over the last three months. Corporate insiders own 0.06% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Fox Run Management L.L.C. Acquires New Stake in Pfizer, Inc. (PFE)” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://sportsperspectives.com/2017/09/19/fox-run-management-l-l-c-acquires-new-stake-in-pfizer-inc-pfe.html.

Pfizer, Inc. (NYSE:PFE) traded down 0.267% during midday trading on Tuesday, hitting $35.455. The company had a trading volume of 5,556,173 shares. The stock has a 50 day moving average price of $33.71 and a 200-day moving average price of $33.53. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $35.84. The stock has a market capitalization of $210.86 billion, a PE ratio of 25.936 and a beta of 1.00.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The business had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The company’s revenue was down 1.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.64 earnings per share. On average, equities analysts predict that Pfizer, Inc. will post $2.56 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Friday, August 4th were issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.60%. The ex-dividend date of this dividend was Wednesday, August 2nd. Pfizer’s dividend payout ratio is presently 94.12%.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply